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Abstract 
 
Background:  Cryptococcus is the most common cause of meningitis amongst adults living with 
HIV in sub-Saharan Africa. Global burden estimates are critical to guide prevention strategies 
and determine treatment needs.    
Methods:  We used 2014 Joint United Nations Programme on HIV/AIDS estimates of adults 
with HIV and antiretroviral therapy (ART) coverage. Estimates of CD4<100 cells/µL, virologic 
failure incidence, and loss-to-follow up were from published multinational cohorts in low- and 
middle-income countries. We calculated those at risk for cryptococcal infection, specifically 
those with CD4<100 cells/µL not on ART, and those with CD4<100 cells/µL on ART but lost-
to-follow up or with virologic failure. Cryptococcal antigenemia (CRAG) prevalence by country 
was derived from 46 studies globally. Based on CRAG prevalence in each country/region, we 
estimated the annual numbers developing and dying from cryptococcal meningitis.  
Findings:  We estimated an average CRAG prevalence of 6·0% among CD4<100 cells/µL, with 
278,000 (95% CI 195,500 to 340,600) CRAG+ persons globally and 223,100 (95% CI 150,600 
to 282,400) incident cryptococcal meningitis cases globally in 2014. Sub-Saharan Africa 
accounted for 73% of the estimated cryptococcal meningitis cases (162,500 cases; 95% CI 
113,600 to 193,900). Cryptococcal-related deaths were estimated at 181,100 (95% CI 119,400 to 
234,300) globally, with 135,900 (75%) (95% CI 91,000 to 161,000) deaths in sub-Saharan 
Africa.  Globally, Cryptococcus was responsible for 15% of AIDS-related mortality (95% CI 
10% to 19%). 
Interpretation: Our analysis highlights the substantial ongoing burden of HIV-associated 
cryptococcal disease, primarily in sub-Saharan Africa.  
 
Funding Source: None.   
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Introduction 
Cryptococcus is the most common cause of meningitis among adults living with human 
immunodeficiency virus (HIV) in sub-Saharan Africa.1-3 Despite antiretroviral therapy (ART) 
expansion, prevalence of cryptococcal infection remains largely unchanged in low- and middle-
income countries (LMICs), unlike high-income countries (HICs).4-7  Estimates of national, 
regional, and global burden of cryptococcal meningitis are critical to guide prevention strategies 
and determine needs for diagnostic tests, antifungal medicines, and medical supplies, such as 
lumbar puncture needles and manometers.  
In 2008, the global annual incidence of cryptococcosis was estimated as 957,900 cases per 
year (range, 371,700-1,544,000 cases).8 This estimate was based on published cohorts from the 
pre-ART era, and the wide confidence interval (CI) indicates the high level of uncertainty of 
these estimates.  Since then, extensive ART expansion has occurred; acquired immunodeficiency 
syndrome (AIDS)-related deaths have declined by 45% from 2.0 to 1.1 million deaths.9 The 
significance of asymptomatic cryptococcal antigenemia (CRAG) as a precursor to symptomatic 
meningitis and death has been further defined,10-13 and more CRAG prevalence data have been 
published (Figure 1). 
Recently, the World Health Organization (WHO), U.S. President’s Emergency Plan for 
AIDS Relief (PEPFAR), and U.S. Department of Health and Human Services have 
recommended CRAG screening among those with CD4+ T-cell count <100 cells/µL who are not 
receiving effective ART.14-16  CRAG screening coupled with preemptive antifungal therapy has 
proven survival benefit,10, 12, 17  and has been incorporated into HIV national guidelines in 
Botswana, Kenya, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, U.S., and 
Zimbabwe with consideration elsewhere. Estimating the cryptococcal disease burden helps 
stakeholders weigh the costs and resources required for hospital-based meningitis treatment 
versus investment of resources into preemptive CRAG screen-and-treat strategy.18  
We provide an updated estimate of the global incidence of HIV-associated cryptococcal 
disease using published Joint United National Programme on HIV and AIDS (UNAIDS) data on 
HIV incidence, ART access, retention-in-care, and published CRAG prevalence data.   
 
Methods 
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Global Estimates of HIV Infection 
We used UNAIDS 2014 country-level estimates of global incidence and cases of HIV infection 
(Table 1); specifically published estimates of adults living with HIV, adults (age 15+) receiving 
ART, and percent receiving ART among adults eligible for ART per WHO 2010 guidelines 
(CD4 <350 cells/µL) via UNAIDS 2014 Spectrum Estimates,19 UNAIDS GAP Report,20 and 
WHO Global Health Observatory database.21 Each UNAIDS and WHO estimate was originally 
published with a low and high estimate range as a measure of uncertainty. Using the estimates of 
those with a CD4<350 cells/µL on ART, and those eligible for ART, we calculated the ART gap 
(not receiving ART but CD4<350 cells/µL). We used UNAIDS and WHO reports for estimates 
of CD4<100 cells/µL,22 CD4 100-200 cells/µL, virologic failure,23 and loss to follow up.23 See 
Table 1, and Appendix (p2 to 8) for further details. 
For each point estimate a 95% CI was obtained. To further account for bias and limitations of the 
primary literature, the 95% CI was widened by adding/subtracting 1.5 times the difference 
between the right and left limits respectively. Thus, the uncertainty ranges described in the 
Methods below and in Table 1 are conservatively wider than 95% CI from the published 
literature. 
 
Estimate of persons at risk for Cryptococcal Disease 
We defined the total number of persons at risk for cryptococcosis by country and region, defined 
as: 1) adults with CD4<100 cells/µL not on ART, and 2) adults with CD4<100 cells/µL on ART 
but either lost to follow up or with virologic failure. Those who start ART but do not have 
virologic failure, and are CRAG negative, have no risk of developing cryptococcal infection. The 
estimate of adults with a CD4 <100 cells/µL was 22·5% (Range: 19% to 26%) among those with 
CD4<350 cells/µL in LMICs. 22, 24 In HICs, 18·5% (Range: 16% to 21%) of those with a 
CD4<350 cells/µL were estimated to have a CD4<100 cells/µL.22, 24 Thus, we estimated the 
number with CD4<100 cells/µL on ART from the ART percent coverage (ART percent coverage 
x ART eligible (CD4<350 cells/µL) x proportion with CD4<100 cells/µL, accounting for 
uncertainty around those estimates (Appendix pages 2 and 3).  
Based on a UNAIDS systematic review, we assumed 16% (Range: 12% to 20%) of persons 
initiating ART retained-in-care had virologic failure at 12 months.23  After completing one year 
on ART, we assumed the virologic failure incidence to be one-third of that in the first year at 
Burden of Cryptococcus 
5 
5·3% (95% CI 4·0% to 6·6%).23, 25-27 This review cites observational data from Canada, the U.S., 
and the United Kingdom with similar frequencies of viral suppression at 12 months.28-30 
Retention-in-care is based on country level estimates from UNAIDS,19  and where missing, we 
used continental mean estimates.  
 
CRAG Prevalence 
We then estimated the total number of persons with CRAG using blood CRAG prevalence 
studies from 1989 to 2016, either in the published literature, or posters presented at conferences, 
among outpatient populations for 17 African countries, 5 Asian countries, 5 Latin American 
countries, the U.S., and United Kingdom (Figure 1). CRAG prevalence studies of solely inpatient 
populations were excluded, as prevalence may be higher in those presenting to the hospital, and 
not representative of the asymptomatic outpatient population that is ideal for CRAG screening. 
For countries with available data, CRAG prevalence amongst persons with a CD4<100 cells/µL 
was used for that specific country along with the associated 95% CI by Fisher’s Exact test (see 
Appendix p4, p10). For countries without CRAG prevalence data, we used the pooled, weighted 
continental mean estimate.  Thereafter, we estimated the number with prevalent CRAG by 
country and region by multiplying persons at risk for cryptococcal disease by the CRAG 
prevalence of the country/region (described above and in Table 1).  
 
CRAG-positive persons who develop Cryptococcal Meningitis 
Not all CRAG-positive patients develop cryptococcal meningitis. Estimates of CRAG-positive 
adults who go on to develop symptomatic cryptococcal meningitis were from published cohort 
studies.10-12, 31-33 We estimated 70% (Range: 56% to 84%) of CRAG+ persons progressed to 
develop cryptococcal disease or died without diagnosis, unless treated with ART and/or 
preemptive fluconazole (Appendix p5). Without ART or preemptive fluconazole therapy, we 
assumed 95% (Uncertainty Range: 90% to 100%) progression in all regions (expert opinion of 
authors) with a 5% competing risk of death from other causes or comorbid conditions.10, 11, 34-36    
 
CRAG-negative persons at risk for Cryptococcal Infection 
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The cryptococcal meningitis incidence amongst persons with CD4<200 cells/µL who were 
initially blood CRAG-negative, before initiating ART is 5·14 per 100 person-years.33 This is 
estimated from the only publication available for estimating incidence of cryptococcal meningitis 
before initiation of ART in Uganda, and for this we assumed an incidence range of 2·6 to 9 
cryptococcal events per 100 person-years. In high-income countries, we assumed the risk of 
development of cryptococcal meningitis was 50% lower, due to more intensive monitoring and 
additional second-line ART options.   For those persons with CD4<200 cells/µL, initially 
prevalent CRAG-negative status and not receiving ART, we assumed a competing risk of 
starting ART or death of 50% (i.e. 500/1000 person-years).  
 
Annual Incidence of Cryptococcal Meningitis 
Annual incidence of cryptococcal meningitis includes the estimation of those CRAG-positive 
persons who developed symptomatic meningitis, both in care newly initiating ART with 
unmasking disease and those not in care and/or not on ART with AIDS progression. 
 
Cryptococcal Meningitis Deaths 
We estimated 1-year mortality in low-income countries (LICs) as 70% (Uncertainty Range: 59% 
to 81%) after cryptococcal meningitis for those in care and 100% for those not in care (Appendix 
p5).30, 47-52  For middle-income countries, we presumed 1-year mortality of 40% (Uncertainty 
Range: 34% to 46%), based on summary statistics of outcomes of those receiving amphotericin 
B and fluconazole, and 60% for those not originally in care (i.e., not receiving ART).37, 38  In 
Europe (including Eastern Europe and Russia), we estimated 1-year mortality to be 30% for 
those in care and 45% for those not in care (expert opinion of authors). In North America, we 
estimated 1-year mortality to be 20% for those in care and 30% for those not in care.39   
 
Uncertainty Analysis 
To account for parameter uncertainty in the primary data, we used probability distributions to 
describe a range for each point estimate of interest. We varied each value in our model 
simultaneously with, sampled from a priori defined probability distributions. The outputs from 
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this uncertainty analysis generated CIs for each parameter. Full details of each parameter and 
distribution are available in the Appendix (pages 7 and 8).  
We used empirical data, when available, to define distributions (Appendix p7 and 8). We 
used standard beta distributions for binomial data, and normal distribution for continuous 
estimates. Using Microsoft Excel 2013, we randomly selected a value for each parameter within 
the appropriate distribution, and used the combination of these values to estimate the number of 
CRAG-positive persons, annual incidence of cryptococcal meningitis, and number of deaths 
from cryptococcal meningitis for each region. Using 50,000 iterations, we obtained empirical 
distributions corresponding to posterior distributions calculated by Monte Carlo simulations.  
These distributions were used to generate a point estimate (posterior mean) and Monte Carlo CIs 
from the lower 2·5% and higher 97·5% for the estimates of CRAG, meningitis, and fatality from 
cryptococcal disease.   
Role of the funding source 
The sponsor of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. 
 
Results 
 
In December 2013, 31·8 million (range 30·1 to 33·7 million) adults were living with HIV 
globally, with 21·7 million (20·7 to 23·0 million) living in sub-Saharan Africa. Globally, 19·5 
million adults were eligible for ART (CD4<350 cells/µL) by WHO 2010 guidelines, with 11·3 
million actually receiving ART. Globally, 8·2 million people had CD4<350 cells/µL but not 
receiving ART, with 5·2 million of these individuals in sub-Saharan Africa. We estimated 4·3 
million adults have a CD4<100 cells/µL globally, and of these, 1·8 million (42%) were not on 
ART. This group is at particularly high risk for opportunistic infections, including 
cryptococcosis. In 2013, there were an estimated 1·4 million (range 1·1 to 1·6 million) AIDS-
related deaths globally, per UNAIDS estimates. 
We estimated an average global CRAG prevalence of 6·0% (95% CI 5·8% to 6·2%) among 
persons with CD4<100 cells/µL, with the number with cryptococcal antigenemia (CRAG-
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positive) to be 278,000 (95% CI 195,500 to 340,600) persons globally in 2014 (Figure 2). 
Annually, we estimate there are 223,200 (95% CI 150,600 to 282,400) cases of cryptococcal 
meningitis globally, with 73% of cases (n=162,500, 95% CI 113,600 to 193,900) occurring in 
sub-Saharan Africa (Supplemental Figure 2, Appendix p9). The region with the second highest 
incidence was Asia & Pacific (20% of total), with an annual incidence of 43,200 (95% CI 25,300 
to 64,700) cases of cryptococcal meningitis. Annual fatalities from cryptococcal meningitis are 
estimated at 181,100 (95% CI 119,400 to 234,300) deaths globally, with 135,900 (75%) (95% CI 
93,900 to 163,900) deaths occurring in sub-Saharan Africa. Globally, cryptococcal meningitis 
results in 15% of AIDS-related mortality (95% CI 10% to 19%). Table 2 highlights the countries 
with the highest incidence of cryptococcal meningitis.  Table 3 specifies cryptococcal infection 
burden by region. Supplemental Table 1 provides country-level listing of data for all parameters 
considered in the model.  
 
 
Discussion 
 
We estimated the global incidence of cryptococcal meningitis to be substantial at 223,100 cases 
annually (95% CI 150,600 to 282,400), resulting in 181,100 (95% CI 119,400 to 234,300) annual 
deaths in 2014. Sub-Saharan Africa continues to bear the brunt of this burden. We estimated 
cryptococcal meningitis causes 15% (95% CI 10% to 19%) of AIDS-related deaths globally. 
Although the absolute number of cryptococcal deaths has decreased since the prior 2008 
estimate,8 the proportion of AIDS-related mortality remains similar. Our estimates, and others, 
imply that cryptococcosis remains the second most common cause of AIDS-related mortality, 
only narrowly behind tuberculosis.40,41-45  These updated accurate disease estimates enable 
appropriate ordering of essential antifungals, diagnostics, and medical supplies.  
Importantly, prevention of cryptococcal disease has demonstrated survival benefit and is 
cost-saving to healthcare systems.18, 38, 46, 47  The cost of CRAG screening programs needs to be 
appreciated in the context of the treatment costs for cryptococcal meningitis patients in LMICs. 
For example, the per patient cost of cryptococcal meningitis treatment in Uganda with 
amphotericin B and fluconazole is $510 for two weeks.38 Consolidation and maintenance therapy 
with fluconazole for one year costs $60 per meningitis survivor ($0·15 per 200mg fluconazole) 
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in LMICs.48 Thus, with an annual estimated incidence of 12,200 meningitis cases in Uganda, 
$6·2 million would be required for initial meningitis diagnosis and treatment. Conversely, if 
CRAG screening costs $4·00 49 plus $24·60 for the WHO-recommended preemptive treatment 
regimen,9 screening those 110,500 persons at risk for cryptococcal disease in Uganda with 
CD4<100 cells/µL and preemptively treating those 15,500 CRAG+ costs $822,600, which is 
13% of the cost of meningitis treatment with >40% better long-term survival.50  
Evaluation of results 
Compared with prior 2008 estimates,8 our 2014 estimates are lower, as the HIV/AIDS landscape 
has changed with rapid ART expansion and a 45% decrease in AIDS-related mortality from 2005 
to 2013 in sub-Saharan Africa.9  We also used a different methodologic approach using CRAG 
prevalence, as CRAG+ status is a known predictor of progression to cryptococcal meningitis.  
Country-specific CRAG prevalence data were less available previously. 
Additionally, we compared our estimates to the few published estimates of the national 
incidence of cryptococcal meningitis. Our model estimated 2,945 U.S. cases of cryptococcal 
meningitis annually. In the U.S., an estimated 3,400 recognized cryptococcal meningitis 
hospitalizations were identified by ICD-9 hospital billing codes, of which two-thirds were HIV-
related.39 In South Africa during 2015, the national reported laboratory-confirmed cryptococcal 
meningitis cases were 6174 and an additional 4295 CRAG+ persons without documented 
meningitis.5  We estimated 21,400 cases in South Africa for 2014. This discrepancy likely 
reflects a proportion of persons living with AIDS not in care, undiagnosed, and lost-to-follow-up 
who do not receive a reported laboratory-confirmed diagnosis.  An estimated 554,990 South 
Africans are living with AIDS,5 and the median CD4 count among ART-naïve persons entering 
care was 150 cells/µL in 2015.51  We estimated 382,400 South Africans with a CD4<100 
cells/µL would be at risk for cryptococcal disease. In 2015, the South African National Health 
Laboratory Service processed 360,000 CD4 counts <100 cells/µL (~10% of nationwide total) of 
which ~80% are estimated to be from unique individuals.51  
One limitation of this estimate is our use of UNAIDS 2014 data, when 2016 data are 
available. The most recent figures were not used, as the 2014 UNAIDS estimates have published 
numbers of those with CD4<350 cells/µL by country. We used these numbers to estimate 
CD4<100 cells/µL and thereby estimate the population at risk for cryptococcal infection. 
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UNAIDS no longer publishes the number with CD4<350 cells/µL by country; thus a 2016 
estimate would require us to project the number with a CD4<100 cells/µL based on the 
proportion of HIV-infected, thereby adding more uncertainty to our estimates. At the time of this 
publication, 2016 data were also missing in several critical country estimates.  
Further limitations of our analysis are related to lack of UNAIDS country data for HICs. A 
second limitation is that many countries do not have any CRAG prevalence data available, so 
estimates were extrapolated from countries in the region with CRAG data available. There is also 
significant heterogeneity in studies reporting CRAG prevalence.  Solely inpatient CRAG 
prevalence studies were excluded; however, some studies included symptomatic and 
asymptomatic persons, which may overestimate point estimates for CRAG prevalence and yet 
underestimate the progression to symptomatic meningitis, if already symptomatic. CRAG 
prevalence studies used different testing methods (latex agglutination vs. lateral flow assay) with 
different sensitivities for detection. There are relatively few studies which assess progression of 
asymptomatic CRAG+ to symptomatic meningitis or death.10-12, 31, 32 Our estimate of 
asymptomatic cryptococcal antigenemia progression to symptomatic meningitis was based on a 
weighted average of mixed studies where many were not treated at all.11 Thus progression to 
meningitis/death may be an underestimate and will vary with access to timely ART.  To account 
for bias and limitations of the primary data, we performed a probabilistic sensitivity analysis that 
generated Monte Carlo CIs according to the probability distribution of possible outcomes. Given 
the limited high quality source data, we broadened our estimates of uncertainty of the primary 
data by widening our CIs to use 99.7% CI with three standard deviations above and below the 
weighted averages of included studies. Furthermore, our estimates of meningitis incidence and 
death are based on point-prevalence data over the past 10 years. These estimates do not reflect 
averages of historic trends nor are they based on dynamic disease models to predict future 
disease incidence. However, CRAG prevalence data has been relatively constant by country over 
time.10, 13, 52  Notably, the proportion of AIDS-related mortality due to cryptococcosis has 
remained stable from prior estimates.8  However with improvements in ART access and 
retention-in-care, estimates of incidence of cryptococcal meningitis should correspondingly 
decrease over time. 
Despite global improvement in access to ART, the number HIV-infected persons with a CD4 
count <100 cells/µL entering care is still substantial at ~20-25% of those presenting to care.53 
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Thus, the annual number with cryptococcal infection remains high at 278,000 globally. 
Cryptococcal meningitis is an excellent metric of HIV treatment program failure. In 2016, no 
HIV-infected person should develop cryptococcal disease, yet due to challenges with: late 
diagnosis, linkage to care, ART access, retention in care, and virologic failure on ART,24, 53, 54 
the often final event in a failed cascade of HIV care is the development of cryptococcal 
meningitis. Until linkage to comprehensive HIV care can be improved, cryptococcal screening 
programs are a worthy investment that identify populations at high risk for death. In order to 
reduce AIDS-related deaths, ensuring that those with CD4 counts <100 cells/µL are CRAG 
screened, preemptively treated (if CRAG+), and initiated on ART remains critical.  
Our analysis highlights the ongoing substantial burden of HIV-associated cryptococcal 
disease, primarily in sub-Saharan Africa but also in Asia. Ensuring timely HIV testing and rapid 
linkage-to-care remains an urgent priority. CRAG screening and preemptive fluconazole 
treatment should be part of a routine package of enhanced care for those presenting late with 
AIDS at time of entering into HIV care. 
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Table 1: Model Inputs and Assumptions 
Variable Estimate Range of Uncertainty Source 
Adults living with HIV 31·8 million 30.1 million to 33.7 million UNAIDS 2013 
Adults with CD4<350 19·5 million 18.5 million to 20.7 million UNAIDS 2013 
CD4<100 cells/µL of those CD4<350 cells/µL  
Low/Middle-Income 
Countries 
22·5% 19% to 26% 22, 24, 55-57 
High-Income Country  18·5% 16% to 21% 22, 24, 55-57 
CD4 100-200 cells/µL of those CD4<350 cells/µL 
• Low/Middle-Income 
Countries 
27·5% 24% to 31% 22, 24, 55-57 
• High-Income Countries 31·5% 29% to 34%  
Adults receiving ART 11·3 million 10·4 million to 12·7 million UNAIDS 2013 
New Initiation of ART 2·3 million 1·8 million to 2·8 million UNAIDS 2013, 2014 
Retention in Care (year 1) Country-specific, regional estimate, weighted pooled average. 
Total LTFU estimated at 1.1 million in 2014.  
UNAIDS 2015 
Virologic failure (year 1) 16% 12% to 20% UNAIDS 2015, 23 
Virologic failure (year 2+) 5·33% 4·0% to 6·6% 25-27 
At risk for cryptococcal 
infection 
1. CD4 < 100 cells/µL not on ART 
2. CD4 < 100 cells/µL on ART but LTFU or virologic failure 
3.  CD4 100-200 cells/µL not on ART, LTFU, or virologic failure 
CD4 100 to 200 cells/µL no 
ART, LTFU, or virologic 
failure 
25% of those with CD4<100 cells/µL not on ART, or LTFU, 
or virologic failure 
10, 33 
CRAG prevalence for 
countries with multiple 
sources 
Weighted average of all 
sources 
Computed 95% CI Figure 1 
CRAG prevalence for countries without sources Regional weighted average Computed 95% CI 
CRAG negative progression to CRAG+ (without effective ART) CD4<200 cells/µL  
Low/Middle-Income 
Countries 
5·14 events per 100 person-
years 
2·6 to 9·0 events per 100 
person-years 
33 
High-Income Country 2·57 events per 100 person-
years 
1·3 to 4·5 events per 100 
person-years 
50% of 33 
CRAG+ who develop Cryptococcal Meningitis  
• In care without 
preemptive treatment 
70% 56% to 84% 10-12, 31, 32 
• Not in care 95% 90% to 100% 10-12, 31, 32 
Deaths from Cryptococcal Meningitis (1 year mortality) 
• Low-Income Country 70% 59% to 81% 50, 58-63 
• Middle-Income Country 40% 34% to 46% 37, 38, 58, 64 
• North America 20% 12·5 to 27·5% 39, 65 
• Europe 30% 25% to 35%  
Death not in care (all regions) 1·5x higher N/A 34 
ART: antiretroviral therapy. LTFU: Lost to follow up.  
* Retention-in-care and virologic failure in years 2+ are assume to be 33% of their year 1 value. † Refer to 
Supplemental Methods for further details. Boxed letters correspond to Supplemental Figure 1 
A 
B 
C 
D 
E 
F 
G 
H 
I 
J 
K 
L 
M 
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Table 2: Countries with the Highest Incidence of Cryptococcal Meningitis 
Country 
Annual 
incidence 
of CM 
Number at 
Risk (CD4<100 
cells/µL) 
Cost of 
screening all at 
risk* 
% of HIV 
budget to screen 
all at risk66 
1. Nigeria 27,100 325,900  $1,303,437  0·23% 
2. South Africa 21,400 382,400  $1,529,685  0·09% 
3. Mozambique 18,600 184,300  $737,228 0·28% 
4. India 18,300 209,900  $839,502  0·06% 
5. Uganda 12,200 110,500  $441,933  0·08% 
6. Ethiopia 9,600 60,600  $242,561  0·06% 
7. Kenya 9,000 84,700  $329,138  0·08% 
8. Tanzania 8,400 117,200  $468,959 0·15% 
9. Democratic Republic 
of Congo 
8,400 51,200  $204,889 0·24% 
10. Zimbabwe 8,100 92,400  $369,621  N/A 
11. Indonesia 6,600 58,900  $235,564 0·27% 
12. Zambia 5,000 66,200  $264,611  0·10% 
*Based on presumed cost of CRAG Lateral Flow Assay test of $3 per test delivered price for resource-
limited areas, with an additional $0·50 added for laboratory labor, and $0·50 for profit/overhead costs. 
Although not every person at risk will present to care, this gives an estimate of the magnitude of 
budgetary resources necessary to start screening.  
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Table 3: Burden of cryptococcal infection by region  
 Total CRAG+ Annual Burden of 
Cryptococcal Meningitis 
Deaths from 
Cryptococcal Meningitis 
Sub-Saharan 
Africa 
204,300 
(148,400 to 237,800) 
162,500  
(113,600 to 193,900) 
135,900  
(93,900 to 163,900) 
Asia & Pacific 52,300  
(32,900 to 74,100) 
43,200  
(25,300 to 64,700) 
39,700  
(20,600 to 59,700) 
Caribbean 1,800  
(1,300 to 2,200) 
1,400  
(1,000 to 1,800) 
700  
(500 to 900) 
Latin America 7,000  
(3,600 to 11,100) 
5,300  
(2,600 to 8,900) 
2,400  
(1,100 to 4,400) 
North America 3,700 
(3,000 to 4,600) 
3,000  
(2,300 to 3,700) 
700  
(500 to 1,000) 
North Africa & 
Middle East 
3,600  
(2,600 to 5,000) 
3,300  
(2,400 to 4,500) 
1,900  
(1,300 to 2,700) 
Europe 5,200 
(4,000 to 6,500) 
4,400  
(3,400 to 5,600) 
1,800  
(1,300 to 2,400) 
Global 278,000  
(195,500 to 341,000) 
223,100  
(150,600 to 282,400) 
181,100  
(119,400 to 234,300) 
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Figure legends: 
Figure 1: CRAG Prevalence studies among HIV-infected outpatient populations from 1989 to 
2016. Estimates of US and UK were not included in final summary estimate of low and middle 
income countries.  Studies of hospitalized populations were not included. For full details of 
population and reference, see Appendix p10.  
 
Figure 2: Annual Incidence of cryptococcal infection by country. Annual number with 
cryptococcal antigenemia (CRAG-positive) estimated at 278,000 (95% CI 195,500 to 340,600) 
persons globally in 2014. 
 
